BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) reached 62.91% versus a 1-year low price of $4.53. The stock was last seen -6.58% lower, reaching at $7.38 on 3/22/2019. At a recent session, the prices were hovering between $7.38 and $7.9. This company shares are 72.22% off its target price of $12.71 and the current market capitalization stands at $870.4M. The recent change has given its price a -14.86% deficit over SMA 50 and -25.83% deficit over its 52-week high. The stock witnessed -15.17% declines, -2.77% declines and 0.68% gains for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found BCRX’s volatility during a week at 4.94% and during a month it has been found around 5.34%.

BioCryst Pharmaceuticals, Inc. (BCRX) Top Holders

Institutional investors currently hold around $747 million or 93.6% in BCRX stock. Look at its top three institutional owners: Baker Bros. Advisors Lp owns $111.46 million in BioCryst Pharmaceuticals, Inc., which represents roughly 12.81% of the company’s market cap and approximately 14.92% of the institutional ownership. Similar statistics are true for the second largest owner, Janus Henderson Group Plc, which owns 12,302,555 shares of the stock are valued at $90.79 million. The third largest holder is Ra Capital Management, Llc, which currently holds $78.67 million worth of this stock and that ownership represents nearly 9.04% of its market capitalization.

BioCryst Pharmaceuticals, Inc. 13F Filings

At the end of December reporting period, 51 institutional holders increased their position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by some 5,294,616 shares, 56 decreased positions by 4,357,385 and 30 held positions by 91,590,819. That puts total institutional holdings at 101,242,820 shares, according to SEC filings. The stock grabbed 21 new institutional investments totaling 1,785,280 shares while 14 institutional investors sold out their entire positions totaling 584,467 shares.

BioCryst Pharmaceuticals, Inc. (BCRX) Analyst Guide

Several analysts have released their opinion on BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), with 1 analysts believing it is a strong buy. Whereas 3 of them predict the stock is a hold. Also, there are 5 buy, 0 sell and 0 strong sell ratings, collectively assigning a 2.22 average brokerage recommendation [T1].